Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
University of Pittsburgh
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Exelixis
Neonc Technologies, Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
M.D. Anderson Cancer Center
Maastricht University Medical Center
Incyte Corporation
Emory University
Dana-Farber Cancer Institute
Iovance Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Thomas Jefferson University
Providence Health & Services
Intensity Therapeutics, Inc.
Xencor, Inc.
Northwestern University
University of Washington
The Netherlands Cancer Institute
National Cancer Centre, Singapore
Bristol-Myers Squibb
National Cancer Institute (NCI)
Universitätsklinikum Hamburg-Eppendorf
Bristol-Myers Squibb
AIO-Studien-gGmbH
Incyte Corporation
Incyte Corporation
Lytix Biopharma AS
Threshold Pharmaceuticals